Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Sankyo will invest $1.5 million in the Alameda, Calif., company and pay a $1 million licensing fee. GLYC, which
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury